Browse the evidence

A higher percentage of patients receiving retatrutide achieved weight losses of ≥5%, 10%, 15%, and 20% compared to placebo.

Retatrutide may be particularly effective for patients aiming for significant weight loss.

Retatrutide treatment for 48 weeks resulted in a least-squares mean percentage change in body weight of -24.2% in the 12 mg group compared to -2.1% in the placebo group.

Retatrutide may be an effective treatment option for significant weight loss in adults with obesity.

A weight reduction of 5% or more occurred in 100% of participants who received 8 mg of retatrutide.

The 8 mg dose of retatrutide is highly effective for achieving at least a 5% weight loss in this population.

A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group compared to 22.4% in the placebo group.

Semaglutide may help reduce liver fibrosis in patients with MASH.

In the 10-mg tirzepatide group, 56% of participants achieved resolution of MASH without worsening of fibrosis compared to 10% in the placebo group (difference of 46 percentage points; P<0.001).

Tirzepatide may be an effective treatment option for patients with MASH and moderate to severe fibrosis.

In the 5-mg tirzepatide group, 44% of participants achieved resolution of MASH without worsening of fibrosis compared to 10% in the placebo group (difference of 34 percentage points; P<0.001).

Tirzepatide may be an effective treatment option for patients with MASH and moderate to severe fibrosis.

Semaglutide treatment led to a mean change in the WOMAC pain score of -41.7 points compared to -27.5 points with placebo (P<0.001).

Semaglutide may significantly reduce pain in obese individuals with knee osteoarthritis.

Participants in the semaglutide group had a greater improvement in SF-36 physical-function score (mean change, 12.0 points) compared to the placebo group (mean change, 6.5 points; P<0.001).

Semaglutide may improve physical function in obese individuals with knee osteoarthritis.

The mean weight loss after 3 months of semaglutide treatment was 6.7 kg, equivalent to 5.9%.

Practitioners can expect significant weight loss in patients treated with semaglutide over 3 months.

The mean weight loss after 6 months of semaglutide treatment was 12.3 kg, equivalent to 10.9%.

Practitioners can expect continued weight loss in patients treated with semaglutide over 6 months.

87.3% of patients achieved weight loss of 5% or more after 6 months.

Practitioners can expect a high proportion of patients to achieve at least 5% weight loss with semaglutide.

Liraglutide, 3.0 mg, leads to a mean percentage body weight reduction of -8.82% compared to -0.54% with placebo over 24 weeks.

Liraglutide can be considered as an effective adjunct therapy for weight management in patients struggling after metabolic surgery.

Semaglutide 2.4 mg once weekly significantly reduces body weight by approximately 15%, with simultaneous improvement in cardiometabolic risk factors and physical functioning in people with obesity.

Practitioners can consider semaglutide as an effective treatment option for weight loss in obese patients.

Tirzepatide has recently demonstrated that body weight reduction exceeding 20% in people with obesity is feasible.

Tirzepatide may be considered for patients seeking substantial weight loss.

In adults with obesity, GLP-1 receptor agonists demonstrate 15% to 20% weight loss.

GLP-1 receptor agonists can be considered effective for weight management in obese adults.

Tirzepatide (15 mg once weekly) resulted in weight loss of up to 17.8% after 72 weeks of therapy.

Tirzepatide is an effective option for weight loss in adults without diabetes.

Semaglutide (2.4 mg once weekly) resulted in weight loss of up to 13.9% after 68 weeks.

Semaglutide is a viable weight loss treatment for adults without diabetes.

GLP-1 receptor agonists and co-agonists are efficacious for weight loss with safety concerns predominantly gastrointestinal.

Practitioners should consider GLP-1 RAs for weight management, noting gastrointestinal side effects.

Long-term adherence to a healthy lifestyle is key in reducing the risk of CVD and diabetes mellitus.

Practitioners should encourage long-term healthy lifestyle changes to reduce chronic disease risk.

Both single-set and multiple-set resistance training produce similar increases in muscular strength, muscle mass, muscle quality, and IGF-1 in untrained older women after 12 weeks.

Practitioners can use either single or multiple sets in resistance training for older women to achieve similar benefits.

Liraglutide effectively reduces body weight and body fat through mechanisms involving reduced appetite and lowered energy intake.

Liraglutide can be considered as a pharmacotherapy option for weight management in patients with obesity.

Semaglutide 2.4 mg weekly significantly reduces Major Adverse Cardiovascular Events (MACE) in obese patients without type 2 diabetes, independent of the magnitude of weight loss.

If you have obesity (BMI ≥ 27) but no diabetes, weekly semaglutide (2.4 mg) is a proven therapy to significantly lower your risk of heart attack, stroke, and cardiovascular death. This benefit happens through direct protection of your blood vessels and reduction of inflammation, not just by making you lose weight. To get the best results, you must pair the medication with a gradual dose increase to minimize stomach issues, and you must actively engage in resistance training and eat enough protein to prevent muscle loss.

GLP1-RA treatment is associated with improvements in restrained eating and emotional eating behavior compared with placebo.

GLP1-RAs may help improve eating behaviors in this population.

Obesity as a treatment indication was associated with a higher likelihood of achieving a 10% or greater weight reduction (AOR, 2.46).

Patients with obesity may experience better weight loss outcomes compared to those with type 2 diabetes.